Daniel L. Hertz

4.3k total citations · 2 hit papers
132 papers, 2.7k citations indexed

About

Daniel L. Hertz is a scholar working on Oncology, Pharmacology and Genetics. According to data from OpenAlex, Daniel L. Hertz has authored 132 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Oncology, 40 papers in Pharmacology and 33 papers in Genetics. Recurrent topics in Daniel L. Hertz's work include Cancer Treatment and Pharmacology (56 papers), Pharmacogenetics and Drug Metabolism (39 papers) and Estrogen and related hormone effects (27 papers). Daniel L. Hertz is often cited by papers focused on Cancer Treatment and Pharmacology (56 papers), Pharmacogenetics and Drug Metabolism (39 papers) and Estrogen and related hormone effects (27 papers). Daniel L. Hertz collaborates with scholars based in United States, Italy and United Kingdom. Daniel L. Hertz's co-authors include Howard L. McLeod, Elizabeth Smith, James M. Rae, Maryam B. Lustberg, Charles L. Loprinzi, N. Lynn Henry, Bryan P. Schneider, Dawn L. Hershman, Thomas J. Smith and Cynthia Chauhan and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Daniel L. Hertz

126 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update

2020 615 citations Daniel L. Hertz, Maryam B. Lustberg et al. Journal of Clinical Oncology profile →
Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group

2019 369 citations Stuart A. Scott, Daniel L. Hertz et al. profile →

Peers

Daniel L. Hertz

ONCOL

PHARM

DERMA

GENET

Jamie L. Renbarger United States

Marina Elena Cazzaniga Italy

John W. Kugler United States

Αngelos Koutras Greece

Naoki Nagata Japan

Shigemi Matsumoto Japan

John J. Grygiel Australia

Umesh Chaudhari United States

Tom R. Fitch United States

Axel Holstege Germany

Jamie L. Renbarger United States

Daniel L. Hertz

806 ×0.5

ONCOL

311 ×0.4

PHARM

507 ×1.2

96 ×0.2

DERMA

53 ×0.2

GENET

Citations per year, relative to Daniel L. Hertz Daniel L. Hertz (= 1×) peers Jamie L. Renbarger

Countries citing papers authored by Daniel L. Hertz

Since Specialization

Citations

This map shows the geographic impact of Daniel L. Hertz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel L. Hertz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel L. Hertz more than expected).

Fields of papers citing papers by Daniel L. Hertz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel L. Hertz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel L. Hertz. The network helps show where Daniel L. Hertz may publish in the future.

Co-authorship network of co-authors of Daniel L. Hertz

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel L. Hertz. A scholar is included among the top collaborators of Daniel L. Hertz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel L. Hertz. Daniel L. Hertz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nazzal, Mustafa, et al.. (2025). Review of the contribution of clinical and genetic factors to the racial disparity in taxane-induced peripheral neuropathy. Critical Reviews in Oncology/Hematology. 211. 104739–104739. 1 indexed citations

Hertz, Daniel L., Mary Anne Tanay, Cindy Tofthagen, et al.. (2025). Patient-reported strategies for prevention and treatment of chemotherapy-induced peripheral neuropathy. Supportive Care in Cancer. 33(2). 142–142. 1 indexed citations

Patel, Jai N., Chen Jiang, Kouros Owzar, et al.. (2024). Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance). The Pharmacogenomics Journal. 24(2). 6–6.

Tao, Xueting, et al.. (2024). Impact of chemotherapy-induced peripheral neuropathy permanence on patients' preference to discontinue chemotherapy.. Journal of Clinical Oncology. 42(16_suppl). 12046–12046. 1 indexed citations

Gersch, Christina L., N. Lynn Henry, Karen L. Smith, et al.. (2024). Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms. Pharmacogenetics and Genomics. 34(4). 126–129. 1 indexed citations

Hertz, Daniel L., Chad Bousman, Howard L. McLeod, et al.. (2024). Recommendations for pharmacogenetic testing in clinical practice guidelines in the US. American Journal of Health-System Pharmacy. 81(16). 672–683. 8 indexed citations

Zirpoli, Gary, William E. Barlow, G. Thomas Budd, et al.. (2023). Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221. Journal of the National Comprehensive Cancer Network. 21(11). 1172–1180.e3. 15 indexed citations

Hertz, Daniel L., D. Max Smith, Stuart A. Scott, Jai N. Patel, & J. Kevin Hicks. (2023). Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy. Clinical Pharmacology & Therapeutics. 114(4). 768–779. 22 indexed citations

Pasternak, Amy L., et al.. (2023). Risk of Toxicity From Topical 5‐Fluorouracil Treatment in Patients Carrying DPYD Variant Alleles. Clinical Pharmacology & Therapeutics. 115(3). 452–456. 2 indexed citations

10.

Hertz, Daniel L., Cindy Tofthagen, Emanuela Rossi, et al.. (2023). Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy. Supportive Care in Cancer. 32(1). 48–48. 6 indexed citations

11.

Pasternak, Amy L., Oxana Crysler, Paul Swiecicki, et al.. (2023). Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines Who are Suspected DPYD Variant Carriers Based on a Genetic Data Repository. Clinical Pharmacology & Therapeutics. 114(2). 356–361. 1 indexed citations

12.

Kasvosve, Ishmael, et al.. (2022). Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective. Pharmacogenomics and Personalized Medicine. Volume 15. 613–652. 4 indexed citations

13.

Hertz, Daniel L., Julie A. Douglas, Robert M. Miller, et al.. (2022). Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms. Supportive Care in Cancer. 30(10). 8059–8067. 5 indexed citations

14.

Fang, Fang, et al.. (2021). SLCO1B3 Polymorphisms and Clinical Outcomes in Kidney Transplant Recipients Receiving Mycophenolate. Pharmacogenomics. 22(17). 1111–1120. 2 indexed citations

15.

Poznak, Catherine Van, Evan L. Reynolds, Cherry L. Estilo, et al.. (2020). Osteonecrosis of the jaw risk factors in bisphosphonate‐treated patients with metastatic cancer. Oral Diseases. 28(1). 193–201. 7 indexed citations

16.

Hertz, Daniel L., Kelley M. Kidwell, Feng Li, et al.. (2018). Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy. Clinical Cancer Research. 24(15). 3602–3610. 45 indexed citations

17.

Dolan, M. Eileen, Heather E. Wheeler, Eric R. Gamazon, et al.. (2017). Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. Clinical Cancer Research. 23(19). 5757–5768. 63 indexed citations

18.

Hertz, Daniel L., Alison A. Motsinger‐Reif, Amy Drobish, et al.. (2013). CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Annals of Oncology. 24(6). 1472–1478. 91 indexed citations

19.

Hertz, Daniel L., Alison A. Motsinger‐Reif, Amy Drobish, et al.. (2012). CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Research and Treatment. 134(1). 401–410. 72 indexed citations

20.

Hertz, Daniel L.. (1991). An analysis of rubber under strain from an engineering perspective. 123(12). 14–21. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact